A novel and safe approach for treating cognitive disorders
January 8, 2024Umecrine Cognition attends the JP Morgan 42nd Annual Healthcare Conference 2024 in San FranciscoSTOCKHOLM – January 8, 2024. Umecrine Cognition today announces that the company will attend the JP Morgan 42nd Annual Healthcare Conference in San...
November 28, 2023Umecrine Cognition presents preclinical results showing significant decreases in PBC-like symptomology and neuroinflammationStockholm, November 28, 2023 – Umecrine Cognition AB today announced positive preclinical results that indicate normalizing effects of the clinical...
November 17, 2023Umecrine Cognition raises further funding for the clinical development of golexanoloneSTOCKHOLM – November 17, 2023. Umecrine Cognition today announces that the company has performed a capital raise amounting to SEK 30,4 million, to...
Our drug projects
GABAA receptor modulating steroid antagonists: our scientific focus
Our lead product candidate, golexanolone, is a novel small molecule GABAA receptor-modulating steroid antagonist in development for the treatment of neurological disorders caused by overactivation of GABA-A receptors by the neurosteroid allopregnanolone.